Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome-Reference-Cited by-同舟云学术

Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome

Published:2019-03-15 Issue:6 Volume:98 Page:1383-1392
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Diamantopoulos Panagiotis T.^ORCID, ,Kontandreopoulou Christina-Nefeli,Symeonidis Argiris,Kotsianidis Ioannis,Pappa Vassiliki,Galanopoulos Athanasios,Vassilakopoulos Theodoros,Dimou Maria,Solomou Eleni,Kyrtsonis Marie-Christine,Siakantaris Marina,Angelopoulou Maria,Kourakli Alexandra,Papageorgiou Sotirios,Christopoulou Georgia,Roumelioti Maria,Panayiotidis Panayiotis,Viniou Nora-Athina

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-019-03650-w.pdf

Reference43 articles.

1. Krishnakumar R, Kraus WL (2010) The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39:8–24

2. Carey LA, Sharpless NE (2011) PARP and Cancer - if it’s broke, don’t fix it. N Engl J Med 364(3):277–279

3. Bürkle A (2001) PARP-1: a regulator of genomic stability linked with mammalian longevity. Chembiochem. 2:725–728

4. Decker P, Muller S (2002) Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 3:275–283

5. Bouchard VJ, Rouleau M, Poirier GG (2003) PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 31:446–454

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The genetics of myelodysplastic syndromes and the opportunities for tailored treatments;Frontiers in Oncology;2022-10-20

2. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome;Blood Advances;2021-11-23

3. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine;Leukemia & Lymphoma;2021-11-05

4. Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment;Experimental Hematology & Oncology;2021-11-03

5. PARP1 as a prognostic biomarker for human cancers: a meta-analysis;Biomarkers in Medicine;2021-11